0001143313-23-000114.txt : 20231023
0001143313-23-000114.hdr.sgml : 20231023
20231023135624
ACCESSION NUMBER: 0001143313-23-000114
CONFORMED SUBMISSION TYPE: 25-NSE
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20231023
DATE AS OF CHANGE: 20231023
EFFECTIVENESS DATE: 20231023
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: NAVIDEA BIOPHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000810509
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 311080091
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26520
FILM NUMBER: 231339680
BUSINESS ADDRESS:
STREET 1: 4995 BRADENTON AVENUE
STREET 2: SUITE 240
CITY: DUBLIN
STATE: OH
ZIP: 43017
BUSINESS PHONE: 6147937500
MAIL ADDRESS:
STREET 1: 4995 BRADENTON AVENUE
STREET 2: SUITE 240
CITY: DUBLIN
STATE: OH
ZIP: 43017
FORMER COMPANY:
FORMER CONFORMED NAME: NEOPROBE CORP
DATE OF NAME CHANGE: 19940714
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NYSE AMERICAN LLC
CENTRAL INDEX KEY: 0001143313
IRS NUMBER: 522127241
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: 11 Wall Street
CITY: New York
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-656-5414
MAIL ADDRESS:
STREET 1: 11 Wall Street
CITY: New York
STATE: NY
ZIP: 10005
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE MKT LLC
DATE OF NAME CHANGE: 20120514
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Amex
DATE OF NAME CHANGE: 20090402
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Alternext US LLC
DATE OF NAME CHANGE: 20081009
25-NSE
1
primary_doc.xml
X0203
0001143313
NYSE AMERICAN LLC
0000810509
NAVIDEA BIOPHARMACEUTICALS, INC.
000-26520
5600 Blazer Parkway, Suite 200
Dublin
OH
OHIO
43017-7550
(614) 793-7500
Common Stock
17 CFR 240.12d2-2(b)
Nicolas Connolly
Analyst, Regulation
2023-10-23
EX-99.25
2
ruleprovisionnotice.htm
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES
NYSE American LLC ("NYSE American" or the "Exchange") hereby notifies the Securities and Exchange Commission (the "Commission") of its intention to remove the entire class of Common Stock (the "Security") of Navidea Biopharmaceuticals, Inc. (the "Company") from listing and registration on the Exchange on November 03, 2023, pursuant to the provisions of Rule 12d2-2(b) because, in the opinion of the Exchange, the Securities are no longer suitable for continued listing and trading on the NYSE.
NYSE American has determined that the Company is no longer suitable for listing pursuant to Section 1009(a) of the NYSE American Company Guide (the "Company Guide") as the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide by the end of the maximum 18-month compliance plan period, which expired on July 28, 2023.
On July 28, 2023, the Exchange determined that the Securities of the Company should be suspended from trading and directed the preparation and filing with the Commission of this application for the removal of the Securities from listing and registration on the NYSE American. The Company was notified on July 28, 2023.
Pursuant to the above authorization, a press release regarding the proposed delisting was issued and posted on the Exchange's website on July 28, 2023.
The Company had a right to appeal to a Committee of the Board of Directors of the Exchange (the 'Committee') the determination to delist the Common Stock, provided that it filed a written request for such a review with the Secretary of the Exchange within seven calendar days of receiving notice of the delisting determination. The Company filed such a request on August 4, 2023, within the specified time period. On October 05, 2023, the Committee issued a decision in which it upheld the Exchange's previously announced determination to delist the Company's Common Stock. Consequently, all conditions precedent under SEC Rule 12d2-2(b) to the filing of this application have been satisfied.